Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

计划入组 21 人 · 首次发布于 2017 年 12 月 15 日

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

计划入组 29 人 · 首次发布于 2021 年 3 月 18 日

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

计划入组 120 人 · 首次发布于 2023 年 3 月 15 日

γδ T-PD-1 Ab Cells therapy(Changzhou No.2 People’S Hospital)

MV-anti-PD1

CT-011

Cambridge Antibody Technology

New Zealand

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

Camrelizumab Shows Promise in Initially Unresectable NSCLC

Junshi Biosciences Achieves Regulatory Milestone with First Domestic Subcutaneous Anti-PD-1 Antibody Application in China

LaNova Medicines Initiates Phase 1 Trial of LM-299, Anti-PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors